The cooling-heat medicine Compound Kushen injection significantly improved the sensitivity of gefitinib on less sensitive NSCLC cells in a combinatorial fashion through the PI3K/AKT/mTOR signaling pathway [27]. Here, AKT1 is linked to non-small cell lung carcinoma.